Thomas A Stamey

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. ncbi request reprint The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?
    Thomas A Stamey
    Department of Urology, School of Medicine, Stanford University, Stanford, California 94305, USA
    J Urol 172:1297-301. 2004
  2. ncbi request reprint Volume indexes of total, free, and complexed prostate-specific antigen enhance prediction of extraprostatic disease extension in men with nonpalpable prostate cancer
    Yoshio Naya
    Department of Urology, University of Texas M D Anderson Cancer Center, Houston 77030 4095, USA
    Urology 62:1058-62. 2003
  3. ncbi request reprint Genetic profiling of Gleason grade 4/5 prostate cancer: which is the best prostatic control tissue?
    Thomas A Stamey
    Department of Urology, School of Medicine, Stanford University, California 94305, USA
    J Urol 170:2263-8. 2003
  4. ncbi request reprint Comparative gene and protein expression in primary cultures of epithelial cells from benign prostatic hyperplasia and prostate cancer
    Amy Rose
    Department of Urology, Stanford University School of Medicine, Stanford, CA 94305 5118, USA
    Cancer Lett 227:213-22. 2005
  5. ncbi request reprint Hepsin and maspin are inversely expressed in laser capture microdissectioned prostate cancer
    Zuxiong Chen
    Department of Urology, School of Medicine, Stanford University, Stanford, California 94305, USA
    J Urol 169:1316-9. 2003
  6. ncbi request reprint Vitamin D receptor start codon polymorphism (FokI) and prostate cancer progression
    Yue Xu
    Department of Urology, Stanford University School of Medicine, Stanford, California 94305, USA
    Cancer Epidemiol Biomarkers Prev 12:23-7. 2003
  7. ncbi request reprint Can volume measurement of the prostate enhance the performance of complexed prostate-specific antigen?
    Yoshio Naya
    Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4095, USA
    Urology 60:36-41. 2002
  8. ncbi request reprint Polymorphisms in the androgen receptor and type II 5 alpha-reductase genes and prostate cancer prognosis
    Atsuko Shibata
    Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California 94305 5405, USA
    Prostate 52:269-78. 2002
  9. ncbi request reprint Complexed prostate-specific antigen as a staging tool: results based on a multicenter prospective evaluation of complexed prostate-specific antigen in cancer diagnosis
    Samir S Taneja
    Department of Urology, New York University School of Medicice, NY, USA
    Urology 60:10-7. 2002
  10. ncbi request reprint Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml
    Thomas A Stamey
    Department of Urology, School of Medicine and Department of Statistics, Stanford University, Stanford, CA, USA
    J Urol 167:103-11. 2002

Collaborators

Detail Information

Publications17

  1. ncbi request reprint The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?
    Thomas A Stamey
    Department of Urology, School of Medicine, Stanford University, Stanford, California 94305, USA
    J Urol 172:1297-301. 2004
    ..We assessed how well preoperative serum prostate specific antigen (PSA) reflects the largest cancer in consecutive untreated radical prostatectomies during the last 20 years at Stanford University...
  2. ncbi request reprint Volume indexes of total, free, and complexed prostate-specific antigen enhance prediction of extraprostatic disease extension in men with nonpalpable prostate cancer
    Yoshio Naya
    Department of Urology, University of Texas M D Anderson Cancer Center, Houston 77030 4095, USA
    Urology 62:1058-62. 2003
    ..To analyze the ability of volume-adjusted total, complexed, and free prostate-specific antigen (PSA) to predict organ-confined cancer at radical prostatectomy in patients with nonpalpable disease...
  3. ncbi request reprint Genetic profiling of Gleason grade 4/5 prostate cancer: which is the best prostatic control tissue?
    Thomas A Stamey
    Department of Urology, School of Medicine, Stanford University, California 94305, USA
    J Urol 170:2263-8. 2003
    ..We examined the variation in gene expression profiles of prostate cancer caused by zone specific genes...
  4. ncbi request reprint Comparative gene and protein expression in primary cultures of epithelial cells from benign prostatic hyperplasia and prostate cancer
    Amy Rose
    Department of Urology, Stanford University School of Medicine, Stanford, CA 94305 5118, USA
    Cancer Lett 227:213-22. 2005
    ....
  5. ncbi request reprint Hepsin and maspin are inversely expressed in laser capture microdissectioned prostate cancer
    Zuxiong Chen
    Department of Urology, School of Medicine, Stanford University, Stanford, California 94305, USA
    J Urol 169:1316-9. 2003
    ....
  6. ncbi request reprint Vitamin D receptor start codon polymorphism (FokI) and prostate cancer progression
    Yue Xu
    Department of Urology, Stanford University School of Medicine, Stanford, California 94305, USA
    Cancer Epidemiol Biomarkers Prev 12:23-7. 2003
    ..Additional studies with a larger sample size and investigation of the functional significance of the FokI polymorphism in prostate cancer cells are warranted...
  7. ncbi request reprint Can volume measurement of the prostate enhance the performance of complexed prostate-specific antigen?
    Yoshio Naya
    Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4095, USA
    Urology 60:36-41. 2002
    ..05). In the 109 men with a total prostate volume of <30 cm(3), at 90% sensitivity the specificity of cPSA and cPSAD was better than that of percent fPSA. In conclusion, volume-based cPSA can modestly enhance the performance of cPSA...
  8. ncbi request reprint Polymorphisms in the androgen receptor and type II 5 alpha-reductase genes and prostate cancer prognosis
    Atsuko Shibata
    Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California 94305 5405, USA
    Prostate 52:269-78. 2002
    ..Cytosine-adenine-guanine repeat length of the androgen receptor gene and the A49T and V89L polymorphisms of the 5 alpha-reductase (SRD5A2) gene have been associated with prostate cancer...
  9. ncbi request reprint Complexed prostate-specific antigen as a staging tool: results based on a multicenter prospective evaluation of complexed prostate-specific antigen in cancer diagnosis
    Samir S Taneja
    Department of Urology, New York University School of Medicice, NY, USA
    Urology 60:10-7. 2002
    ..Therefore, cPSA could be applied as an accurate predictor of ECE independently or in a nomogram along with other predictive variables...
  10. ncbi request reprint Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml
    Thomas A Stamey
    Department of Urology, School of Medicine and Department of Statistics, Stanford University, Stanford, CA, USA
    J Urol 167:103-11. 2002
    ..However, benign prostatic hyperplasia (BPH) is a common cause of serum PSA values between 2 and 10 ng./ml. A better understanding of the relationships among serum PSA, prostate cancer and BPH is important...
  11. ncbi request reprint The era of serum prostate specific antigen as a marker for biopsy of the prostate and detecting prostate cancer is now over in the USA
    Thomas A Stamey
    Department of Urology, Stanford University School of Medicine, Stanford, California, USA
    BJU Int 94:963-4. 2004
  12. ncbi request reprint More information on prostate specific antigen and prostate cancer
    Thomas A Stamey
    J Urol 170:457-8. 2003
  13. ncbi request reprint Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: lack of significance of secondary cancers
    Masanori Noguchi
    Department of Urology, Kurume University School of Medicine, Japan
    J Urol 170:459-63. 2003
    ..We evaluated secondary cancers in the prostate in relation to predictions of pathological stage and prognosis...
  14. ncbi request reprint Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter
    Wolfgang Horninger
    Department of Urology, University of Innsbruck, Austria
    Urology 60:31-5. 2002
    ..The use of cPSA as a single test was found to enhance detection of prostate cancer over that of testing with tPSA and PSA ratios in men with tPSA values in the range of 2 to 4 ng/mL...
  15. ncbi request reprint Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens
    Alphaeus M Wise
    Department of Epidemiology, Tulane University, New Orleans, Louisiana, USA
    Urology 60:264-9. 2002
    ..To examine the histologic details of small, independent cancers compared with the largest (index) tumor and their impact on prostate-specific antigen (PSA) failure in 486 men treated only by radical retropubic prostatectomy (RRP)...
  16. ncbi request reprint Re: Pathologic features of prostate cancer found at population-based screening with a four-year interval
    Thomas A Stamey
    J Natl Cancer Inst 94:227-9. 2002
  17. ncbi request reprint Frequent HIN-1 promoter methylation and lack of expression in multiple human tumor types
    Ian Krop
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, D740C, Boston, MA 02115, USA
    Mol Cancer Res 2:489-94. 2004
    ..Thus, silencing of HIN-1 expression and methylation of its promoter occurs in multiple human cancer types, suggesting that elimination of HIN-1 function may contribute to several forms of epithelial tumorigenesis...